Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions

The application of model-informed drug discovery and development (MID3) approaches in the early stages of drug discovery can help determine feasibility of drugging a target, prioritize between targets, or define optimal drug properties for a target product profile (TPP). However, applying MID3 in early discovery can be challenging due to the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data at this stage. Early Feasibility Assessment (EFA) is the application of mechanistic PKPD models, built from first principles, and parameterized by data that is readily available early in drug discovery to make effective dose predictions. This manuscript demonstrates the ability of EFA to make accurate predictions of clinical effective doses for nine approved biotherapeutics and outlines the potential of extending this approach to novel therapeutics to impact early drug discovery decisions.

Automated summary

The application of model-informed drug discovery and development (MID3) approaches in the early stages of drug discovery can help determine drug feasibility, prioritize targets, and define optimal drug properties. However, applying MID3 in early discovery can be challenging due to a lack of pharmacokinetic (PK) and pharmacodynamic (PD) data. Early Feasibility Assessment (EFA) uses mechanistic PKPD models and readily available data to make effective dose predictions.